ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activitiesZURICH, ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

Cell line development plays a key role in the identification of biological targets and commercial manufacturing of biotherapeutics. Despite its importance, the process faces a number of challenges, ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...

Over the past decade, biologics development has moved from artisanal experimentation to a data-driven, platform-based discipline. Analytical depth has improved. Process integration has matured. Yet ...

STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development ...